SG11201704500VA - Antibody binding to neuropilin 1 and use thereof - Google Patents

Antibody binding to neuropilin 1 and use thereof

Info

Publication number
SG11201704500VA
SG11201704500VA SG11201704500VA SG11201704500VA SG11201704500VA SG 11201704500V A SG11201704500V A SG 11201704500VA SG 11201704500V A SG11201704500V A SG 11201704500VA SG 11201704500V A SG11201704500V A SG 11201704500VA SG 11201704500V A SG11201704500V A SG 11201704500VA
Authority
SG
Singapore
Prior art keywords
neuropilin
antibody binding
antibody
binding
Prior art date
Application number
SG11201704500VA
Inventor
Do-Hyun Nam
Yeup Yoon
Jae Hyun Lee
Jin Ku Lee
Original Assignee
Samsung Life Public Welfare Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samsung Life Public Welfare Foundation filed Critical Samsung Life Public Welfare Foundation
Publication of SG11201704500VA publication Critical patent/SG11201704500VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201704500VA 2014-12-03 2015-12-03 Antibody binding to neuropilin 1 and use thereof SG11201704500VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140171949 2014-12-03
PCT/KR2015/013102 WO2016089126A1 (en) 2014-12-03 2015-12-03 Antibody against neuropilin 1 and use thereof

Publications (1)

Publication Number Publication Date
SG11201704500VA true SG11201704500VA (en) 2017-06-29

Family

ID=56092001

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201704500VA SG11201704500VA (en) 2014-12-03 2015-12-03 Antibody binding to neuropilin 1 and use thereof

Country Status (9)

Country Link
US (1) US10364289B2 (en)
EP (2) EP3241844B1 (en)
JP (1) JP6475835B2 (en)
KR (1) KR101784451B1 (en)
CN (1) CN107108743B (en)
AU (1) AU2015355731B2 (en)
CA (1) CA2969402C (en)
SG (1) SG11201704500VA (en)
WO (1) WO2016089126A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3467508A4 (en) * 2016-06-03 2020-04-29 Samsung Life Public Welfare Foundation Anti-nrp1 antibody screening method
KR101985299B1 (en) * 2016-06-03 2019-09-03 삼성전자주식회사 Anti-c-Met/anti-Nrp1 bispecific antibody
CN111133099B (en) * 2017-08-23 2023-12-01 普罗赛拉治疗公司 Use of neuropilin-1 (NRP 1) as a cell surface marker for isolation of human cardiac ventricular progenitor cells
TW202126685A (en) * 2019-09-24 2021-07-16 德商百靈佳殷格翰國際股份有限公司 Anti-nrp1a antibodies and their uses for treating eye or ocular diseases
CN113388586B (en) * 2021-06-15 2024-01-02 广西医科大学 Oncolytic virus NDV-NRP1 and construction method and application thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
ATE87659T1 (en) 1986-09-02 1993-04-15 Enzon Lab Inc BINDING MOLECULES WITH SINGLE POLYPEPTIDE CHAIN.
FR2611064B1 (en) 1987-02-13 1989-06-16 Schvoerer Max METHOD OF MARKING OBJECTS BY MICRO-CRYSTALS WITH MEMORY EFFECT AND MARKERS FOR IMPLEMENTING SAME
SE456223B (en) 1987-02-25 1988-09-19 Sunds Defibrator DISC REFINOR PAINTING ELEMENT
DE3852304T3 (en) 1987-03-02 1999-07-01 Enzon Lab Inc Organism as carrier for "Single Chain Antibody Domain (SCAD)".
DE3884529T2 (en) 1987-03-20 1994-04-28 Creative Biomolecules Inc LEADER SHARES FOR THE PRODUCTION OF RECOMBINANT PROTEINS.
JPH02500876A (en) 1987-03-20 1990-03-29 クリエイティブ・バイオマリキュールズ・インコーポレーテッド Recombinant polypeptide products and methods for their production, isolation and purification
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
WO1999029729A2 (en) 1997-12-09 1999-06-17 Children's Medical Center Corporation Antagonists of neuropilin receptor function and use thereof
WO2001036487A2 (en) 1999-11-15 2001-05-25 Miltenyi Biotec Inc. Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
US7045283B2 (en) 2000-10-18 2006-05-16 The Regents Of The University Of California Methods of high-throughput screening for internalizing antibodies
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
US7906104B2 (en) * 2005-08-04 2011-03-15 The Regents Of The University Of California Methods for detecting pancreatic beta-islet cells and diseases thereof
AU2011253904B2 (en) * 2005-11-08 2014-02-13 Genentech, Inc. Neuropilin antagonists
UA96139C2 (en) * 2005-11-08 2011-10-10 Дженентек, Інк. Anti-neuropilin-1 (nrp1) antibody
EP2250278B1 (en) * 2008-02-21 2023-04-05 Burnham Institute for Medical Research Methods and compositions related to peptides and proteins with c-terminal elements
EP2445536B1 (en) 2009-06-22 2016-06-08 Burnham Institute for Medical Research Methods and compositions using peptides and proteins with c-terminal elements
KR20120106935A (en) * 2009-07-13 2012-09-27 제넨테크, 인크. Diagnostic methods and compositions for treatment of cancer
WO2011143408A1 (en) * 2010-05-13 2011-11-17 Genentech, Inc. Use of neuropilin-1 antagonists for the treatment of cancer
RU2571226C2 (en) * 2010-07-09 2015-12-20 Дженентек, Инк. Antibodies against neyropilin and methods of their application
CN102161703A (en) * 2010-12-30 2011-08-24 厦门大学 Method for preparing monoclonal antibody resisting human neuropilin-1
TW201517916A (en) 2013-03-15 2015-05-16 Lilly Co Eli Therapeutic uses for VEGFR1 antibodies
JP6391676B2 (en) * 2013-05-23 2018-09-19 アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションAjou University Industry−Academic Cooperation Foundation Tumor penetrating peptide specific for neuropilin and fusion protein fused with this peptide

Also Published As

Publication number Publication date
US10364289B2 (en) 2019-07-30
US20170291948A1 (en) 2017-10-12
JP6475835B2 (en) 2019-02-27
EP3783031A1 (en) 2021-02-24
CN107108743B (en) 2021-05-04
KR101784451B1 (en) 2017-10-13
CA2969402C (en) 2019-06-11
EP3241844B1 (en) 2021-04-21
WO2016089126A1 (en) 2016-06-09
CA2969402A1 (en) 2016-06-09
CN107108743A (en) 2017-08-29
EP3241844A4 (en) 2018-09-05
JP2018503364A (en) 2018-02-08
KR20160067767A (en) 2016-06-14
EP3783031B1 (en) 2023-08-02
EP3241844A1 (en) 2017-11-08
AU2015355731B2 (en) 2018-07-26
AU2015355731A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
IL288012A (en) Antibody molecules to lag-3 and uses thereof
IL261188A (en) Antibodies to tigit
IL266259A (en) Antibodies to pd-1 and uses thereof
ZA201903848B (en) Antibodies that specifically bind to human il-15 and uses thereof
ZA201808582B (en) Antibodies to alpha-synuclein and uses thereof
GB201403875D0 (en) Novel antibodies and uses thereof
GB201413913D0 (en) Novel antibodies and uses thereof
ZA201905341B (en) Antibodies specifically binding to human il-1r7
IL247315B (en) Anti-acth antibodies and use thereof
EP3262075C0 (en) Novel antibody binding to tfpi and composition comprising the same
IL251676A0 (en) Antibodies that bind to ccr6 and their uses
IL266516A (en) Antibody binding specifically to cd66c and use thereof
IL269394A (en) Antibodies binding to steap-1
SG11201704500VA (en) Antibody binding to neuropilin 1 and use thereof
PT3239177T (en) Novel egfrviii antibody and composition comprising same
HK1245811A1 (en) Antibodies that bind human c6 and uses thereof
PL3362480T3 (en) Antibody specifically binding to erbb3 and use thereof